Anaplastic lymphoma kinase (ALK) rearrangements are detected in 3–5% of all non-small cell lung cancers (NSCLCs), and ALK tyrosine kinase inhibitors (TKIs) improve the prognosis of patients with ALK-positive NSCLC [2]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.